Tezepelumab produced histologic remission in up to 68.9% of patients aged 12+ with EoE vs 3.5% with placebo at week 24, sustained to week 52.

In phase 3 SHINE-2, 50% of mirikizumab induction responders aged 6 to 17 with moderate to severe UC were in clinical remission at week 52.

At AAP 2026, Justin Wheeler, MD, discussed bowel cleanouts, maintenance therapy, and behavioral strategies for managing constipation in children.

Justin Wheeler, MD, explains how pediatricians can identify constipation across age groups and distinguish overflow incontinence from diarrhea.

A meta-analysis of 52 studies links NO2, SO2, and particulate matter to more pediatric atopic dermatitis visits and higher prevalence.

FDA is investigating tumor reports after Zolgensma for SMA, including 2 confirmed cases of vector integration near the GLI1 oncogene.

Jon Matthew Farber, MD, shares his thoughts on the use of noninvasive brain stimulation for ADHD.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.